Skip to main content

Years after $2B buyout, Nestlé ditches Aimmune's peanut allergy drug Palforzia

Submitted by admin on
snippet

After lackluster sales dampened the initial enthusiasm that came with a $2.1 billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia.

Nestlé has divested Palforzia to U.S.-based allergy specialist Stallergenes Greer for an undisclosed sum, the food giant said Tuesday.

Source
Fierce Pharma

Nestlé to Sell Off Peanut Allergy Treatment, Not the Blockbuster They Hoped

Submitted by admin on
snippet

Nestlé announced Tuesday it will unload the world's only approved peanut allergy treatment just two years after acquiring the company that developed it. Potential patients must've found it easier to just not eat at Five Guys and Texas Roadhouse.

Source
Motley Fool

NICE backs Aimmune’s peanut allergy drug Palforzia for children

Submitted by admin on
snippet

Children in England with peanut allergies could be among the first in Europe to get access to Aimmune’s oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS England.

Source
Pharmaforum

The central figure in Nestlé's $2.6B Aimmune buyout? Covid-19

Submitted by admin on
snippet

Nestlé surprised few this summer when they spent $2.6 billion to buyout Aimmune. The Swiss Butterfingers-and-health conglomerate had long shown more interest in them and Palforzia, their recently approved peanut allergy treatment, than any of the traditional Big Pharmas.

Source
Endpoints

Nestle pays $2 billion to secure Aimmune’s allergy treatment

Submitted by admin on
snippet

Nestle said in a statement that its offer for Aimmune values the California-based biopharmaceutical firm, which it has been working with since 2016 and in which it already has a stake of around 25.6%, at $2.6 billion.

Source
CNBC

A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

Submitted by admin on
snippet

 One is Viaskin, created by DBV Technologies (NASDAQ: DBVT), which functions as an applied skin-patch that gradually increases the amount of tolerance for peanut protein in children with the allergy. The drug, however, is far from perfect and has to overcome severe hurdles before it has a shot at regulatory approval. Aimmune Therapeutics (NASDAQ: AIMT) is another biotech with an innovative treatment aimed at helping children with peanut allergy. 

Source
Motley Fool

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing

Submitted by admin on
snippet

Aimmune Therapeutics Inc. is navigating a host of new challenges as it launches Palforzia, the first peanut allergy immunotherapy to be approved by the US Food and Drug Administration. Most notably, it must get physician practices and individual allergists certified to administer the treatment.

Source
Xconomy

Armed with Nestlé cash, Aimmune grabs experimental food allergy drug form Xencor

Submitted by admin on
snippet

Aimmune has had a good few weeks: It’s just won approval for the first peanut allergy drug at the FDA, then got a $200 million boost from Nestlé, and today it’s using that cash to license a new drug from Xencor.

Source
Fierce Biotech

Aimmune wins approval for peanut immunotherapy, charges 10k+

Submitted by admin on
snippet

The FDA has approved the first treatment for peanut allergy, although it comes with some controversy.

Unlike most of the controversial drugs that come before the FDA, the bulk of questions don’t center around this drug’s effectiveness or side effects.

Source
Endpoints

FDA decision nears on Aimmune's contested peanut allergy drug

Submitted by admin on
snippet

If the Food and Drug Administration follows the advice of its outside advisers, the agency will within days grant the first-ever approval to a drug designed to make peanut allergy sufferers less likely to have a dangerous reaction.

Called Palforzia, the drug was developed by the California-based biotech Aimmune. It's in close competition with a French company called DBV Technologies, which should see the FDA decide on its patch-based peanut allergy treatment by August.

Source
BioPharma Dive